<< Back To Search

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT06083922
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that aim to improve patient outcomes and potentially lead to better management of the disease. Here are some key points about the study:
  • The treatment involves a combination of existing therapies, which may enhance their effectiveness when used together.
  • This study is unique because it looks at how these therapies can work in tandem, rather than testing them individually.
  • Patients will be monitored closely to assess how well the treatment works and to identify any side effects.
  • The goal is to provide a more personalized treatment plan that can adapt to the needs of each patient.
  • Researchers are also interested in understanding the long-term effects of this combination therapy on patients' health and quality of life.
Overall, this study represents an innovative approach to treating blood cancer, with the hope of improving outcomes for patients through a tailored combination of therapies.
Third Opinion AI Generated Synopsis

Trial Summary
The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whether the study drug combination is an effective treatment for these conditions.
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: